Cardiovascular

China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M

Wed, 06 May 2026 12:00:00 -0400

Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.

Bio Korea 2026 kicks off with spotlight on oligonucleotides

Tue, 05 May 2026 12:00:00 -0400

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.

Cytokinetics metrics satisfy in nHCM phase III

Tue, 05 May 2026 12:00:00 -0400

Thanks to a trial design that, according to Evercore ISI analyst Cory Kasimov, “played out exactly as drawn up,” Cytokinetics Inc. hit both of the phase III co-primary endpoints with aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Vanderbilt patent describes 5-HT2B receptor antagonists

Mon, 04 May 2026 09:00:00 -0400

Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension.

Quintuple GLP-1-GIP-PPAR agonist for obesity and diabetes control

Thu, 30 Apr 2026 09:00:00 -0400

A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR α/γ/δ). GLP-1-GIP-Lani enables targeted delivery of the PPAR agonist to cells that express incretin receptors, enhancing weight loss, improving glucose control and reducing inflammation in obese mice. In these models, it surpassed the effects of GLP-1 receptor agonists such as semaglutide and GLP-1-GIP co-agonists such as tirzepatide in reducing body weight, improving glycemic control and enhancing metabolic outcomes during active treatment.

Bio Korea 2026 kicks off with spotlight on oligonucleotides

Wed, 29 Apr 2026 12:00:00 -0400

Supremes weigh in on skinny labels in long-awaited argument

Wed, 29 Apr 2026 12:00:00 -0400

The U.S. Supreme Court’s ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. could either discourage the development of generic drugs under a skinny label or make innovators think long and hard about investing hundreds of millions of dollars in developing new indications for drugs already on the market.

Med-tech companies highlight PFA data as competition intensifies

Mon, 27 Apr 2026 12:00:00 -0400

New data on pulsed field ablation (PFA) presented at Heart Rhythm 2026 in Chicago over the weekend continue to show the benefits and superiority of the technologies in treating patients with atrial fibrillation. The PFA landscape is fast-evolving and med-tech players are jostling for market share with ever-differentiated platforms looking to attract electrophysiologists.

Milestone in Atrium and BMS cardiovascular collaboration

Fri, 24 Apr 2026 09:00:00 -0400

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.

Neolaia synthesizes new CD38 inhibitors

Tue, 21 Apr 2026 09:00:00 -0400

Neolaia Inc. has divulged new quinoline- and quinazoline-carboxamide derivatives acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of atherosclerosis, cancer, inflammation, obesity, Alzheimer’s, autoimmune, cardiovascular and metabolic disorders.

Medtronic leads $100M financing round for Pulnovo

Mon, 20 Apr 2026 12:00:00 -0400

Pulnovo Medical Ltd. secured $100 million in a financing round led by Medtronic plc for its pulmonary artery denervation system to treat pulmonary hypertension.

Alivecor receives CE mark for AI-powered, portable ECG system

Wed, 15 Apr 2026 12:00:00 -0400

Alivecor Inc. has secured CE marking for its Kardia 12L electrocardiogram (ECG) system, which is powered by its KAI 12L AI technology and can detect life-threatening cardiac conditions. Kardia 12L is a portable, AI-guided, 12-lead ECG solution that delivers measurements and interpretations similar to standard 12-lead ECG solutions, right at the point of care. The company said the simplified design will enable faster acquisition of complete ECG data while leading to better patient outcomes.

New China biotech Syneron chases macrocycle frontier

Tue, 14 Apr 2026 12:00:00 -0400

Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.

Everest to acquire Singapore unit of Hasten Bio in $250M deal

Tue, 14 Apr 2026 12:00:00 -0400

Everest Medicines Ltd. has agreed to acquire a Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front, gaining market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.

Stryker agrees to buy Amplitude Vascular Systems for IVL tech

Mon, 13 Apr 2026 12:00:00 -0400

Stryker Corp. has signed a definitive agreement to acquire Amplitude Vascular Systems Inc. (AVS) in a bid to strengthen its Peripheral Vascular portfolio, by adding a revascularization technology.

Lipid reading: Street not deaf to ACC data

Mon, 13 Apr 2026 12:00:00 -0400

Abstracts released ahead of the American College of Cardiology meeting held in late March in New Orleans, along with the start of dosing near the end of January in Novartis AG’s phase IIb trial with siRNA therapy DII-235, also known as BW-20829, perked up the already-lively lipids/heart space.

Fit and fat: Study shows no such thing as metabolically healthy obesity

Mon, 13 Apr 2026 09:00:00 -0400

There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30.

Fit and fat: Study shows no such thing as metabolically healthy obesity

Fri, 10 Apr 2026 12:00:00 -0400

Endospan’s FDA nod for Nexus brings acquisition by Artivion closer

Thu, 09 Apr 2026 12:00:00 -0400

Endospan Ltd. Secured U.S. premarket approval for its Nexus aortic arch stent graft, bringing the company closer to being acquired by Artivion Inc. Under the terms of an existing agreement, Artivion has an option to acquire Endospan at any time within 90 days of the FDA approval.

Everest to acquire Singapore unit of Hasten Bio in $250M deal

Thu, 09 Apr 2026 12:00:00 -0400

New China biotech Syneron chases macrocycle frontier

Wed, 08 Apr 2026 12:00:00 -0400

J&J introduces Varipulse Pro to Europe after CE mark

Wed, 08 Apr 2026 12:00:00 -0400

Johnson & Johnson launched its latest pulsed field ablation (PFA) catheter, Varipulse Pro, in Europe following CE mark approval, bringing another option to electrophysiologists looking to adopt PFA technology. The system features a new pulse sequence with a lower temperature profile and enables ablation that is five times faster than the previous sequence, while achieving equivalent lesions. It represents another significant development in the rapidly evolving PFA market that has transformed cardiac ablation treatment.

VB-19055 exerts antihypertensive effects

Wed, 08 Apr 2026 09:00:00 -0400

Chinese researchers from Zhejiang Yangli Pharmaceutical Technology Co. Ltd. have presented data on an aldosterone synthase inhibitor, VB-19055. Inhibiting aldosterone synthase (CYP11B2) could lead to a potential treatment for cardiovascular-renal-metabolic disorders.

Chengdu Kanghong Pharmaceutical patents new lipoprotein(a)-lowering agents

Tue, 07 Apr 2026 09:00:00 -0400

Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed new compounds targeting apolipoprotein A (ApoA; LPA) and acting as lipoprotein(a)-lowering agents that are potentially useful for the treatment of cardiovascular disorders.

Wegovy pricing deal offers UK reimbursement for heart disease

Wed, 01 Apr 2026 12:00:00 -0400

Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.

Med-tech players join efforts to tackle UK PAD amputations

Wed, 01 Apr 2026 12:00:00 -0400

With cases of peripheral artery disease (PAD) rising across the U.K., and lower limb amputations continuing to increase, med-tech companies joined forces with parliamentarians and health care professionals to push for urgent reform of the vascular sector.

Braveheart finds phase II positive for cardiac myosin inhibitor

Tue, 31 Mar 2026 12:00:00 -0400

Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study.

TY-1 ameliorates hypertrophy in mice with HCM

Tue, 31 Mar 2026 09:00:00 -0400

Hypertrophic cardiomyopathy (HCM) is a condition that limits tolerance to exercise and predisposes people to sudden cardiac death due to mutations in sarcomeric genes. Researchers from Cedars-Sinai Medical Center have tested TY-1, a chemically modified oligonucleotide-based drug inspired by the previously tested EV-YF1, in mice with HCM.

Boston Sci boasts Champion-AF data but strokes signal a concern

Mon, 30 Mar 2026 12:00:00 -0400

Boston Scientific Corp. revealed much-anticipated data from the Champion-AF trial which showed that its Watchman FLX device provides superior protection from bleeding compared to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). The left atrial appendage closure device also proved noninferior to NOACs in reducing stroke, cardiovascular death, or systemic embolism.

Onkure Therapeutics to advance next-generation PI3Kα pan-mutant programs

Fri, 27 Mar 2026 09:00:00 -0400

Onkure Therapeutics Inc. has announced an oversubscribed $150 million private placement which the company intends to use to fund the preclinical and clinical development of its next-generation PI3Kα pan-mutant selective inhibitor candidates in breast cancer and vascular anomalies.